Sarah Albertson

Sarah is a Development Scientist 1 at GentiBio. She brings with her a background in immunoassay product development, clinical immunology, and extensive analytical method development across an array of indications. Prior to Genti, she spent five years contributing to the design and launch of two novel immunoassay product lines at Abcam. In 2017, Sarah and her husband relocated to Seattle where she joined IDRI, designing analytical tools to characterize the immunogenicity of vaccine candidates. Most recently, Sarah led a process analytics team supporting the early-stage cell therapy portfolio of CAR-T and eTCR programs (both autologous and allogeneic) at Juno/Celgene/BMS. Originally a native of Utah, Sarah obtained her BS from the University of Utah with a biology major and chemistry minor.